Headquartered in Cincinnati, OH Fiscal year ends December NASDAQ: MEDP medpace.com
Medpace Holdings, Inc. (Nasdaq: MEDP) is a scientifically-driven, global, full-service clinical contract research organization (CRO) providing Phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries. The company's disciplined operating approach leverages deep regulatory and therapeutic expertise across major areas including oncology, cardiology, metabolic disease, endocrinology, central nervous system, and anti-viral and anti-infective therapies. Medpace's mission is to accelerate the global development of safe and effective medical therapeutics. As of September 30, 2026, the company employs approximately 6,600 people across 46 countries. Updated
Margins did the work at Medpace: net income margin expanded to 19.2% from a year ago, beating earnings estimates on revenue that only edged consensus. The board also cleared a fresh buyback through 2028 and narrowed full-year guidance, so the call Thursday morning is where the backlog math gets tested.
Most ETF names tell you what they own. COWG tells you what it believes in. Pacer US Large Cap Cash Cows Growth Leaders ETF (NYSEARCA:COWG) screens for large-cap US companies generating strong…
Pre-Market Stock Futures: Futures are trading higher after a sluggish start to the holiday-shortened trading week. While stocks started as if it were going to be another risk-off day, they turned positive…
Medpace Holdings, Inc. (Nasdaq: MEDP) is a scientifically-driven, global, full-service clinical contract research organization (CRO) providing Phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries.
24/7 Wall St.'s 12-month price target for MEDP is $742.35, rated Buy. The Wall Street consensus target is $595.92. MEDP price prediction →
